Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease

Claudio Giuliano, Francesca Siani, Liudmila Mus, Cristina Ghezzi, Silvia Cerri, Barbara Pacchetti, Chiara Bigogno, Fabio Blandini

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). The proinflammatory response can occur early in the disease, contributing to nigrostriatal degeneration. Identification of the new molecules, which are able to slow down the degenerative process associated with PD, represents one of the main interests. Recently, natural polyphenols, especially lignans, have raised attention for their anti-inflammatory, antioxidant, and estrogenic activity at a peripheral level. The aim of this study was to evaluate the central effects of chronic treatment with lignan 7-hydroxymatairesinol (HMR/lignan) on neurodegenerative, neuroinflammatory processes and motor deficits induced by a unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats to evaluate the potential neuroprotective properties of this compound.

METHODS: Sprague-Dawley male rats underwent lignan (10 mg/kg) or vehicle treatment (oral) for 4 wk starting from the day of 6-OHDA injection. The degree of nigrostriatal damage was evaluated by immunohistochemistry. Moreover, we performed a quantitative and qualitative assessment of neuroinflammatory process, including phenotypic polarization of microglia and astrocytes. The motor performance was assessed by behavioral tests.

RESULTS: We demonstrated that chronic treatment with HMR/lignan was able to slow down the progression of degeneration of striatal dopaminergic terminals in a rat model of PD, with a consequent improvement in motor performance. Nevertheless, the anti-inflammatory effect of HMR/lignan observed in SNc was not sufficient to protect dopaminergic cells bodies.

CONCLUSION: These results suggest intriguing properties of HMR/lignan at neuroprotective and symptomatic levels in the context of PD.

Original languageEnglish
Pages (from-to)110494
JournalNutrition International
Volume69
Early online dateApr 25 2019
DOIs
Publication statusPublished - Jan 2020

Fingerprint

Lignans
Neuroprotective Agents
Parkinson Disease
Rodentia
Oxidopamine
Anti-Inflammatory Agents
Corpus Striatum
Injections
Process Assessment (Health Care)
Dopaminergic Neurons
Microglia
Polyphenols
hydroxymatairesinol
Astrocytes
Neurodegenerative Diseases
Sprague Dawley Rats
Therapeutics
Antioxidants
Immunohistochemistry

Cite this

Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease. / Giuliano, Claudio; Siani, Francesca; Mus, Liudmila; Ghezzi, Cristina; Cerri, Silvia; Pacchetti, Barbara; Bigogno, Chiara; Blandini, Fabio.

In: Nutrition International, Vol. 69, 01.2020, p. 110494.

Research output: Contribution to journalArticle

@article{4c8cf5868065440ba4adf1791c8e82b1,
title = "Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease",
abstract = "OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). The proinflammatory response can occur early in the disease, contributing to nigrostriatal degeneration. Identification of the new molecules, which are able to slow down the degenerative process associated with PD, represents one of the main interests. Recently, natural polyphenols, especially lignans, have raised attention for their anti-inflammatory, antioxidant, and estrogenic activity at a peripheral level. The aim of this study was to evaluate the central effects of chronic treatment with lignan 7-hydroxymatairesinol (HMR/lignan) on neurodegenerative, neuroinflammatory processes and motor deficits induced by a unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats to evaluate the potential neuroprotective properties of this compound.METHODS: Sprague-Dawley male rats underwent lignan (10 mg/kg) or vehicle treatment (oral) for 4 wk starting from the day of 6-OHDA injection. The degree of nigrostriatal damage was evaluated by immunohistochemistry. Moreover, we performed a quantitative and qualitative assessment of neuroinflammatory process, including phenotypic polarization of microglia and astrocytes. The motor performance was assessed by behavioral tests.RESULTS: We demonstrated that chronic treatment with HMR/lignan was able to slow down the progression of degeneration of striatal dopaminergic terminals in a rat model of PD, with a consequent improvement in motor performance. Nevertheless, the anti-inflammatory effect of HMR/lignan observed in SNc was not sufficient to protect dopaminergic cells bodies.CONCLUSION: These results suggest intriguing properties of HMR/lignan at neuroprotective and symptomatic levels in the context of PD.",
author = "Claudio Giuliano and Francesca Siani and Liudmila Mus and Cristina Ghezzi and Silvia Cerri and Barbara Pacchetti and Chiara Bigogno and Fabio Blandini",
note = "Copyright {\circledC} 2019 Elsevier Inc. All rights reserved.",
year = "2020",
month = "1",
doi = "10.1016/j.nut.2019.04.006",
language = "English",
volume = "69",
pages = "110494",
journal = "Nutrition International",
issn = "0899-9007",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease

AU - Giuliano, Claudio

AU - Siani, Francesca

AU - Mus, Liudmila

AU - Ghezzi, Cristina

AU - Cerri, Silvia

AU - Pacchetti, Barbara

AU - Bigogno, Chiara

AU - Blandini, Fabio

N1 - Copyright © 2019 Elsevier Inc. All rights reserved.

PY - 2020/1

Y1 - 2020/1

N2 - OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). The proinflammatory response can occur early in the disease, contributing to nigrostriatal degeneration. Identification of the new molecules, which are able to slow down the degenerative process associated with PD, represents one of the main interests. Recently, natural polyphenols, especially lignans, have raised attention for their anti-inflammatory, antioxidant, and estrogenic activity at a peripheral level. The aim of this study was to evaluate the central effects of chronic treatment with lignan 7-hydroxymatairesinol (HMR/lignan) on neurodegenerative, neuroinflammatory processes and motor deficits induced by a unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats to evaluate the potential neuroprotective properties of this compound.METHODS: Sprague-Dawley male rats underwent lignan (10 mg/kg) or vehicle treatment (oral) for 4 wk starting from the day of 6-OHDA injection. The degree of nigrostriatal damage was evaluated by immunohistochemistry. Moreover, we performed a quantitative and qualitative assessment of neuroinflammatory process, including phenotypic polarization of microglia and astrocytes. The motor performance was assessed by behavioral tests.RESULTS: We demonstrated that chronic treatment with HMR/lignan was able to slow down the progression of degeneration of striatal dopaminergic terminals in a rat model of PD, with a consequent improvement in motor performance. Nevertheless, the anti-inflammatory effect of HMR/lignan observed in SNc was not sufficient to protect dopaminergic cells bodies.CONCLUSION: These results suggest intriguing properties of HMR/lignan at neuroprotective and symptomatic levels in the context of PD.

AB - OBJECTIVES: Parkinson's disease (PD) is a neurodegenerative disease characterized by loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). The proinflammatory response can occur early in the disease, contributing to nigrostriatal degeneration. Identification of the new molecules, which are able to slow down the degenerative process associated with PD, represents one of the main interests. Recently, natural polyphenols, especially lignans, have raised attention for their anti-inflammatory, antioxidant, and estrogenic activity at a peripheral level. The aim of this study was to evaluate the central effects of chronic treatment with lignan 7-hydroxymatairesinol (HMR/lignan) on neurodegenerative, neuroinflammatory processes and motor deficits induced by a unilateral intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats to evaluate the potential neuroprotective properties of this compound.METHODS: Sprague-Dawley male rats underwent lignan (10 mg/kg) or vehicle treatment (oral) for 4 wk starting from the day of 6-OHDA injection. The degree of nigrostriatal damage was evaluated by immunohistochemistry. Moreover, we performed a quantitative and qualitative assessment of neuroinflammatory process, including phenotypic polarization of microglia and astrocytes. The motor performance was assessed by behavioral tests.RESULTS: We demonstrated that chronic treatment with HMR/lignan was able to slow down the progression of degeneration of striatal dopaminergic terminals in a rat model of PD, with a consequent improvement in motor performance. Nevertheless, the anti-inflammatory effect of HMR/lignan observed in SNc was not sufficient to protect dopaminergic cells bodies.CONCLUSION: These results suggest intriguing properties of HMR/lignan at neuroprotective and symptomatic levels in the context of PD.

U2 - 10.1016/j.nut.2019.04.006

DO - 10.1016/j.nut.2019.04.006

M3 - Article

C2 - 31586482

VL - 69

SP - 110494

JO - Nutrition International

JF - Nutrition International

SN - 0899-9007

ER -